proprotein convertase subtilisin/kexin type 9(English)

• inhibition is an effective strategy in reducing cardiovascular disease risk by lipid-lowering therapy with statins. Approved by the FDA for reducing low-density lipoprotein cholesterol in high-risk patients. Also as PCSK9
• LDL-R, FDA, PCSK, CVD, EGF-A, LDL-C, PCSK9, AAV-PCSK9
• Cardiology, Therapeutic approaches, Atherosclerosis /atherogenic
• https://doi.org…OMES.120.007521
• https://doi.org…acc.2022.05.041
• https://doi.org…NAHA.115.016080
• https://doi.org…NAHA.123.065213